INTRODUCTION
During the past 10-20 years there has been an explosion in the available data on characterization of molecular pathways in cancer cells. This phenomenon has paved the way to a new era of molecular therapeutic agents, with the development of novel compounds that target specific cellular pathways of critical importance in cancer-cell survival. Small molecules, such as multitargeted tyrosine-kinase inhibitors, have made their way from the bench into clinical trials and are now part of the standard clinical armamentarium available against a number of malignancies.
Targeted treatment for urologic cancer is now a reality of standard clinical practice. Most recently, two small-molecule inhibitors (sunitinib and sorafenib) that inhibit multiple receptor tyrosine kinases were approved by the FDA in December 2005 and January 2006 for clinical use in metastatic renal cancer. 1,2 Other targeted strategies, such as cancer vaccines, are currently under investigation, and hold promise for prostate and kidney cancer treatment.
Heat-shock protein 90 (HSP90) is an abundant intracellular protein that is upregulated during cellular stress. 3 Its role in cancer has received much attention in the past decade, given that it is an integral part of the machinery that allows neoplastic cells to escape normal regulation. HSP90 has functions in multiple oncogenic pathways, and might, therefore, be less of a 'moving target' than the other, everchanging components of the unstable genetic profile of a cancer cell. Well-characterized, selective inhibitors of HSP90 have completed phase I trials. To date, more than 20 phase II clinical trials of HSP90 inhibitors are planned or in progress, three of which are in urologic cancers. This article describes the role of HSP90 in urologic malignancy, with a special emphasis on the molecular pathways, the available clinical trials for HSP90 inhibitors, and the potential future avenues of investigation for these promising compounds.
Insight into the molecular biology of cancer has allowed the development of novel therapeutic strategies that target specific oncogenic pathways. Molecular therapeutic strategies are now part of the armamentarium available against urologic malignancy. Among the many targets of interest in urologic cancer, heat-shock protein 90 (HSP90) shows great promise. This molecule has a major role in prostate as well as in renal malignancy. In contrast to other targets, where cancer might escape inhibition via alternative pathways, HSP90 operates at multiple checkpoints in a cancer cell. Its inhibition could, therefore, prove more difficult for neoplastic cells to overcome. Inhibitors of HSP90, such as geldanamycin and its derivatives (17-allylamino-17-demethoxygeldanamycin and 17-dimethylaminoethylamino-17-demethoxygeldanamycin, known as 17AAG and 17DMAG, respectively) are available and have shown activity both in vivo and in vitro. 17AAG is currently being tested for efficacy in humans after having completed phase I trials, while 17DMAG is still in phase I evaluation. Phase II trials of HSP90 inhibitors in urologic malignancy are being conducted in kidney and advanced prostate cancer. Beyond monotherapy, HSP90 inhibitors might also prove to be beneficial in combination therapy with other chemotherapeutic agents in advanced disease. Studies being conducted in prostate cancer will hopefully help to define this potential application better.
HSP90 is a ubiquitous, constitutively expressed protein in eukaryotic cells. HSP90 comprises up to 1-2% of total cellular protein, a proportion that increases by 2-10-fold during environmental stress; this upregulation seems to be a protective mechanism that enhances cell survival. 3,4 Deletion of HSP90 has been shown to be lethal in eukaryotic cells, and chaperone proteins (such as HSP90) are upregulated in many neoplastic processes, 5-7 as well as in urologic cancers in particular. 8, 9 These facts, considered together, point towards a possible protective role of heat-shock proteins in neoplastic processes. 10 After their synthesis, proteins have to be folded in order to acquire their final, functional state. The role of HSP90 as a chaperone in the normal cell encompasses protein folding, translocation between cellular compartments, suppression of protein aggregation, and refolding of inter mediate proteins. 4 A folding pathway can either lead to a functional, properly folded client protein, or to degradation of the same molecule. 11,12 During stress, this dual function helps repair (or 'cleanse') the pool of damaged proteins, and re-establishes homeostasis. 12 Over 100 proteins have been reported to be clients of HSP90. Box 1 lists the most pertinent of these client proteins in urologic malignancy. A more detailed review is available in Wegele H et al., 11 and on the website maintained by Picard. 13 It is believed that mutations of specific client proteins in cancer are sustained by their interaction with HSP90, which might favor survival of a deregulated, neoplastic cell that harbors oncogenes. 10 The structure of HSP90 is illustrated in Figure 1 ; it is a 90 kDa protein that consists of three distinct domains. 14 The N-terminal domain contains an intrinsic ATP-binding site that has a crucial role in the protein's function; this role will be explained below. The middle domain contains a client-protein-binding site that can interact with ATP that is bound to the N-domain. Finally, cytoplasmic HSP90 exists as a dimer, and it is through the C-terminal domain that dimerization occurs. 14 Although HSP90 has a central role in clientprotein processing, it requires interactions with a host of other chaperones, co-chaperones and immunophilins, in order to perform these functions. Table 1 lists key components of the HSP90 protein-processing system. The client protein (a steroid receptor, in Figure 2) Figure 1 Schematic structure of HSP90. HSP90 has three distinct domains, and consists of the N-terminal, middle, and C-terminal regions. A charged region exists between the N-terminal and the middle domain. Benzoquinone ansamycins bind to the N-terminus, where ATP also binds. Novobiocin, a coumarin antibiotic, binds to the C-terminal domain. Homodimerization occurs at the C-terminal domain. Client proteins have been reported to interact with all three domains. Abbreviations: 17AAG, 17-allylamino-17-demethoxygeldanamycin; 17DMAG, 17-dimethylaminoethylamino-17-demethoxygeldanamycin; HSP, heat-shock protein.
dependent process, which will significantly optimize receptor-ligand interaction. 17 In its final conformation, the chaperone-receptor complex will proceed down one of two pathways: it will either bind its ligand and be released from the complex, in order to translocate inside the nucleus and initiate downstream gene transcription, or it will be recycled, through new chaperone interactions. If the ATP-dependent step does not take place, the receptor will eventually undergo ubiqui tinylation (binding of the peptide ubiqui tin to a protein, which marks it for destruction) and ultimately proteasome degradation (Figure 2) . 18, 19 Probably one of the most critical steps in protein processing is, therefore, the ATP-dependent reaction that renders the chaperone-receptor complex capable of binding its ligand, and this is where HSP90 inhibitors exert their action.
HEAT-SHOCK PROTEIN 90 INHIBITORS
Multiple inhibitors of HSP90 have been described (see Box 2). For a more in-depth review of specific HSP90 inhibitors the reader is referred to a review published by Budillon et al. 20 in 2005. Benzoquinone ansamycins are a class of antibiotics that have generated interest because of their ability to revert the malignant phenotype to a normal one, in fibroblasts transformed by Rous sarcoma virus. 21 These antibiotics have also been shown to have HSP90-inhibiting activity. 22 Although controversy surrounded the mechanism of action of these first HSP90 inhibitors, it is now accepted that benzoquinone ansamycins act through the ATP-binding site in the N-terminal domain of the chaperone. These agents prevent ATP binding 23 and, therefore, result in targeting of client proteins for degradation by the proteasome. 24 Observed effects of HSP90 inhibitors on tumors include cell-cycle arrest and apoptosis, as well as reduced invasion, angiogenesis and metastasis. 25 Since HSP90 is essential for the function of normal cells as well as tumor cells, one initial concern in relation to its therapeutic applicability was that inhibition of its functions might not be selective for malignancy. It has, however, been shown through preclinical models that HSP90 inhibitors, given at certain doses, can exert antitumor activity without causing host toxicity. 26 Furthermore, HSP90 inhibitors have been shown to concentrate more in tumor tissue than in normal tissue, 27 which provides a unique opportunity for selective tumor targeting. Finally, HSP90 inhibitors bind with a significantly higher affinity to the chaperone in neoplastic cells than is evident in normal cells. 28 This feature might be the result of increased activity of the chaperone machinery in the tumor cells, which could render tumor cells more vulnerable to HSP90 inhibition, compared with normal cells.
Geldanamycin
Geldanamycin was one of the first benzoquinone ansamycins to be isolated from actinomycete broth (Figure 3) . 29 This compound has shown antitumor activity in vitro as well as in vivo, 30 but its hepatotoxicity profile in preclinical models precluded its use in clinical trials. 30
17-allylamino-17-demethoxygeldanamycin
In a screening study that aimed to identify compounds with less toxicity than geldanamycin, 17-allylamino-17-demethoxygeldanamycin (17AAG) emerged as a promising candidate. 31 This compound exhibited comparable biologic activity to geldanamycin, 32 and had a morefavorable toxicity profile in vivo. Four phase I clinical trials of 17AAG as a single agent have been reported; 33-36 these are outlined in Table 2 . The recommended dosage of 17AAG in phase II studies has varied from 295-450 mg/m 2 intravenously (depending on the treatment schedule), over a 28-day cycle that included a 1-week break from treatment. Reported adverse effects included fatigue, anemia, anorexia, diarrhea, nausea, vomiting, elevations in aspartate aminotransferase and alanine aminotransferase, thrombocytopenia, fever, and possible cardiac and pancreatic toxicity. At the recommended doses, however, 17AAG seemed to be well tolerated, with minimal adverse events. 17AAG is currently being investigated in phase II trials (Table 3) as a single agent and in combination, for the treatment of multiple solid tumors as well as leukemias and lymphomas.
17-dimethylaminoethylamino-17-demethoxy geldanamycin
Most recently, 17DMAG (17-dimethylaminoethylamino-17-demthoxygeldanamycin) has undergone comparison with 17AAG in vitro, and seems to retain the same capacity to bind HSP90 as 17AAG. 37 Furthermore, being water soluble, this compound requires a less complex formulation than 17AAG, and has shown signs of oral bioavailability in vivo in a xenograft model in nude mice, which represents a significant potential advantage. 38 Four phase I studies are underway to investigate the use of 17DMAG in solid tumors.
Other alternatives that inhibit HSP90 and are under development include purine analogs and pyrazole inhibitors of the N-terminal nucleotide pocket, and compounds that bind to a recently identified C-terminal ATP-binding site (Box 2). [39] [40] [41] [42] 
HSP90 IN PROSTATE CANCER Androgen-resistant prostate cancer
One of the current challenges in prostate cancer lies at the frontier of hormone-refractory disease. The transition between the hormone-sensitive and hormone-insensitive state implicates the androgen receptor as a central factor, and detailed reviews of the mechanisms of development of androgen-independent prostate cancer are available. 43, 44 Androgen-receptor expression is amplified in up to 30% of recurrent tumors after androgen deprivation therapy. 45 Although termed androgen-independent, there is evidence to suggest that hormone-refractory prostate cancer might still rely on stimulation of the androgen receptor for sustained growth. This stimulation could take place via ligand binding, 46 or through binding of alternative molecules such as estrogens and progestins (or antiandrogens, in the case of mutated receptors). 47 www.nature.com/clinicalpractice/uro might also take place. These factors include insulin-like growth factor (IGF1), 48 or human epidermal growth factor receptor 2 (also termed HER2 or NEU) through the mitogen-activated protein kinase pathway 49 or the protein kinase B (also known as AKT) pathway (Figure 4) . 50 In fact, HER2/NEU is upregulated (and reaches up to 50% higher than normal levels) in prostate cancer and is, significantly, upregulated further in hormone-refractory disease. 51 There remains, however, a subset of hormone-refractory prostate cancers that might not depend on androgenreceptor expression. These tumors sustain their growth in a way that allows them to bypass the androgen receptor entirely, by using other pathways including the phosphatidylinositol-3 kinase (PI3K)/AKT and STAT3 (signal transducer and activator of transcription 3) pathways. 52 Considering this level of complexity, an ideal treatment for hormone-refractory prostate cancer should target the multiple mechanisms involved in progression to the androgenindependent state. HSP90 inhibitors seem to be promising candidates to achieve this effect, since they inhibit nodal points in multiple survival pathways.
Androgen receptor-HSP90 interaction
The androgen receptor is a client protein of HSP90, and immunohistochemical staining shows that HSP90 is strongly expressed in prostate cancer tissues of all Gleason grades. 53 Studies in vitro and in vivo have confirmed that geldanamycin and 17AAG cause degradation of the androgen receptor in three different prostate cancer cell lines. 54 Not only does 17AAG downregulate the wild-type androgen receptor, but it also has the same effect on mutated androgen receptors. 54 Beyond the direct effect on the androgen receptor, inhibition of HSP90 shows activity at other critical checkpoints in the hormoneresistant cell. HER2/NEU and AKT levels decline after 17AAG administration both in vivo and in vitro. 54 These changes have been observed in correlation with downregulation of the androgen receptor and tumor xenograft inhibition. Although it has not been shown that HSP90 inhibitors downregulate other signaling molecules that are known to be crucial to the hormone-refractory state in prostate cancer cell lines, such downregulation has been established in other models (e.g. IGF1 55 and STAT3 56 ). Taken together, these facts constitute a solid rationale for testing HSP90 inhibitors in prostate cancer. NATURE CLINICAL PRACTICE UROLOGY 595 www.nature.com/clinicalpractice/uro that tumors will progress in most patients despite treatment with these standard therapies, exploration of treatment approaches that can be used in combination with standard treatments is certainly warranted. Since neoplastic cells rely on the HSP90 machinery to sustain oncogene products, inhibition of HSP90 function might render the neoplastic cell more vulnerable to standard antineoplastic treatments, including radiotherapy or chemotherapy. Proof of this effect has been noted in vitro with various prostate cancer and other tumor cell lines. 57, 58 
Clinical trials in prostate cancer
Following on from the solid rationale for use of HSP90 inhibitors in prostate cancer, and the encouraging preclinical in vitro and in vivo studies, a phase II trial has been initiated to test the efficacy of 17AAG monotherapy in the setting of metastatic, hormone-refractory prostate cancer. 59 The study aims to assess the PSA response to 17AAG in patients who have failed primary chemotherapy. Secondary objectives are to determine overall survival, disease-free survival and measurable disease response to 17AAG, as well as to study various markers, such as nuclear factor κB, interleukin 6, and maspin. In addition to this, a phase I combination study of 17AAG and docetaxel at Memorial SloanKettering Cancer Center is currently recruiting patients with hormone-refractory prostate cancer or other solid tumors.
HSP90 IN KIDNEY CANCER Molecular pathways in kidney cancer
Insight gained through studies of hereditary kidney cancer has shed light on the pathways that are critical in sporadic kidney cancer. Two hereditary syndromes, von Hippel-Lindau (VHL) and hereditary papillary renal cancer, will be discussed, which both have potential for HSP90-targeted therapy.
Von Hippel-Lindau disease VHL disease is a hereditary disorder with an autosomal-dominant transmission. Clinical manifestations in this condition include central nervous system lesions (retinal angiomas, cerebellar and spinal hemangio blastomas), and visceral lesions (pancreatic cysts and neuroendocrine tumors, adrenal and extra-adrenal pheochromo cytomas, renal cysts and clear cell carcinoma). Other findings include cystadenomas of the epididymis and broad ligament, and endo lymphatic sac tumors of the inner ear. 60 VHL disease is one of the rare conditions for which a defined intra cellular pathway has been delineated over the past few years ( Figure 5 ).The product of the VHL gene, pVHL, is constitutively expressed; it targets hypoxiainducible factor (HIF) for degradation via the proteasome pathway. In the absence of VHL, HIF is stabilized and upregulates (among other things) the expression of downstream products such as vascular epithelial growth factor, transforming growth factor α and glucose transporter type 1 that generate neo vascularization, mitogenesis and increased glucose uptake respectively. All these events drive tumor development and growth. 61 Targeting HIF for degradation is a potentially promising strategy in a mechanistic approach to this disease. Furthermore, since VHL mutations have been described in up to 57% of sporadic, clear-cell kidney tumors, 62 such a strategy could hold promise for the broader patient population with sporadic, clear-cell renal carcinoma.
Sporadic, papillary type I renal cancer
Sporadic, papillary type I renal cancer is the second most common type of renal cancer; 63 and shares a distinct morphologic phenotype with hereditary papillary renal cell carcinoma (HPRC). 64 HPRC is an autosomal dominant disorder with reduced penetrance; the clinical manifestations of HPRC include bilateral multifocal kidney tumors with a papillary type I histology. The HPRC oncogene was located by linkage analysis on chromosome 7q31.1-34, and missense mutations in the tyrosine kinase domain of MET proto-oncogene (which encodes c-met) were detected in individuals with HPRC. 65 C-met is a membrane receptor tyrosine kinase that binds extracellular hepatocyte growth factor, which triggers auto phosphorylation, and a downstream cascade that culminates in increased mitogenesis, motogenesis and morphogenic differentiation ( Figure 6 ). 66 Targeting c-met might, therefore, be a rational strategy to tackle this pathway.
Clinical trials in kidney cancer
As shown in Box 1, 17AAG is a potent inhibitor of both HIF and c-met, which are both client proteins of HSP90. HIF downregulation by 17AAG has been demonstrated in a renal cell carcinoma cell line, and is independent of the VHL ubiquitinylation pathway. 67 Unfortunately, no in vivo xenograft model to specifically assess the activity of 17AAG in clear cell cancer has been reported. Phase I trials with 17AAG have not included sufficient numbers of patients with kidney cancer to permit speculation on its efficacy in this setting (Box 2). A phase II study is being conducted at the National Cancer Institute that will, hopefully, help to answer this question. The objective of this study is to evaluate the efficacy of 17AAG Although c-met has been shown to be a client protein of HSP90, 68 the role of HSP90 inhibition in papillary type I kidney cancer has not been formally explored. This area remains to be investigated in the future.
HSP90 IN OTHER UROLOGIC MALIGNANCIES Transitional cell carcinoma of the bladder
Controversy exists over the role of HSP90 in bladder cancer. In an immunohisto chemical study of HSP90 expression in urothelial cancer, the HSP90 chaperone was found to be expressed in normal tissue but was expressed to a greater extent in neoplastic cells. 69 In fact, this study showed that low levels of HSP90 expression in tumor specimens correlated with a poor prognosis. Different results were reported in another study that used the same detection methods, where the authors concluded that HSP90 staining was absent in normal tissue and present in tumors, with the strength of staining correlating positively with tumor grade. 70 Further studies are needed to understand the role of HSP90 in transitional cell carcinoma.
Testis cancer
High levels of expression of HSP90 have been reported in human embryonal carcinoma cell lines. 71, 72 No in vitro studies are available that have studied the effects of geldanamycin analogs in these cell lines. Given the high rate of cure in nonseminomatous as well as seminomatous germ-cell tumors, interest in targeting HSP90 might lie in the rare cases where all treatment modalities have failed. In such a scenario, further investigations into the role of HSP90 could hold promise.
PHARMACODYNAMIC EVALUATION OF ANTI-HSP90 ACTIVITY IN UROLOGIC MALIGNANCIES
Unlike other molecularly targeted agents that have been introduced in the treatment of urologic cancers, the efficacy of HSP90 inhibitors is probably a result of chaperone inhibition, which can affect a number of HSP90 client proteins. HSP90 activity in vivo can only be measured indirectly, by monitoring the activity and/or stability of one or more of its client proteins. Informative pharmaco dynamic evaluation of HSP90 inhibition in the context of urologic malignancies must, therefore, take into account the tumor type and its etiology. While pharmacodynamic monitoring of peripheral blood lymphocytes has provided a readily accessible and reproducible index of in vivo biologic activity of HSP90 inhibitors in phase I clinical trials, drug effects in this normal tissue do not necessarily predict tumor-specific activity. In the absence of pVHL, HIF will not be downregulated, and will drive the transcription of downstream factors such as TGF-α, Glut-1 and VEGF, which lead to growth stimulation, increased glucose uptake and increased angiogenesis respectively. Abbreviations: Glut-1, glucose transporter 1; HIF, hypoxia-inducible factor; pVHL, von Hippel-Lindau protein; TGF-α, transforming growth factor alpha; VEGF, vascular endothelial growth factor.
In the context of prostate cancer, therefore, it would be important to monitor drug effects on one or more end points in tumor biopsies: androgen-receptor protein expression, phosphorylation status of protein kinase B, HER2/ NEU expression, MAP kinase activation status, and phosphorylation status of STAT3. These evaluations can be made by techniques such as immuno cytochemistry or tissue microarrays.
In the context of kidney cancer (depending on tumor subtype), c-met receptor expression, HIF protein expression, or expression of HIF target genes-such as those for glucose transporter type 1 and transforming growth factor α-can be monitored. Imaging studies could be considered, to determine changes in neo vascularization or glucose uptake. Similar pharmacodynamic end points for transitional cell carcinoma of the bladder and testis cancer need to be developed, based on careful pre clinical evaluation of the response of these tumors to HSP90 inhibitors.
IMPACT OF GENE POLYMORPHISMS ON RESPONSES TO DRUGS
Cytochrome P450 3A5 (CYP3A5*3) poly morphism might contribute to interindividual differences in CYP3A-dependent drug clearance. Goetz et al. have, however, determined that while CYP3A5*3 polymorphism could alter exposure to 17AAG, this is unlikely to have clinical consequences since 17AG (the metabolite of 17AAG) is also bio active. 34 Likewise, although NAD(P)H quinone oxidoreductase 1 (NQO1) expression has been shown to affect in vitro sensitivity of tumor cells to 17AAG, 25 in their phase I clinical trial Goetz et al. found no difference in drug clearance or toxicity in patients whose cells exhibited decreased NQO1 enzyme activity. 34 It remains to be determined, however, whether NQO1 expression level sensitizes tumor cells to this drug in vivo.
The potential impact on drug sensitivity of polymorphisms in the family of HSP90 genes should also be considered. To date, a low variability has been observed in the coding regions of both HSP90A and HSP90B alleles. 73 For HSP90A, only one missense and one nonsense mutation have been observed. The missense mutant has compromised activity when tested in yeast, 74 but the individual who carried this mutation was a healthy adult. A single missense mutation in HSP90B that resulted in a conservative amino acid change has been reported. Importantly, all of these mutations are in the C-terminal portion of the protein; no mutations in the N-terminal (drug-binding) domains have been identified, to date. The absence of variability in the N-terminal domain (if confirmed) is important for pharmaco genetic reasons. The response of the HSP90A C-terminal missense mutation to N-terminal-inhibitor drugs, however, remains to be determined.
CONCLUSION
The era of targeted molecular therapy potentially holds great promise in the treatment of cancer. HSP90 is an attractive target for the treatment of urologic malignancies, including prostate and kidney cancer. 17AAG is an inhibitor of HSP90 that is currently under investigation for activity in humans as a monotherapy, as well as in combination with other chemotherapeutic agents. The development of this compound, and of other HSP90 inhibitors-from bench to clinic-constitutes a model of translational research that serves as a paradigm for the discovery and validation of new, molecularly targeted cancer drugs. 
